Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Belantamab Mafodotin in Relapsed or Refractory Multiple Myeloma (DREAMM-14)
NCT05064358Phase 2Completed
- Sponsor
- GSK
- Start
- Mar 2022
- Primary completion
- Aug 2024
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs)
- Countries
- 18
01
Overview
A Phase 2 trial of belantamab mafodotin in multiple myeloma (MM), sponsored by GSK. Started Mar 2022; status: completed.
02
Drugs
belantamab mafodotin
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT05064358.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05064358.